In Brief: Trimedyne
This article was originally published in The Gray Sheet
Executive Summary
Trimedyne: Laser firm's Cardiodyne subsidiary files an IDE to commence clinical trials of its holmium-based myocardial laser revascularization system to treat patients suffering from severe angina and myocardial ischemia who either are unresponsive to, or not suitable for, drug therapy and who have failed coronary artery bypass surgery and/or percutaneous transluminal coronary angioplasty. The system features an 8-watt SuperPulse holmium laser, AutoFire interface and ChannelMaker fiber-optic needle device. AutoFire monitors a patient's electrocardiogram and, based on data obtained, automatically creates a channel in the heart wall when the left ventricle is full of blood...